94 related articles for article (PubMed ID: 7196063)
1. Potential effects of edema on the pharmacokinetics of platinum in patients treated with cis-dichlorodiammine platinum (II).
Buice RG; Soloway MS
Res Commun Chem Pathol Pharmacol; 1980 Dec; 30(3):447-57. PubMed ID: 7196063
[TBL] [Abstract][Full Text] [Related]
2. Platinum kinetics in patients treated with cis-dichlorodiammine platinum (II).
Buice RG; Soloway MS
Ther Drug Monit; 1982; 4(3):293-6. PubMed ID: 6890248
[TBL] [Abstract][Full Text] [Related]
3. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II).
Dumas M; d'Athis P; de Gislain C; Escousse A; Guerrin J; Autissier N
Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):430-3. PubMed ID: 4044076
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).
Belt RJ; Himmelstein KJ; Patton TF; Bannister SJ; Sternson LA; Repta AJ
Cancer Treat Rep; 1979; 63(9-10):1515-21. PubMed ID: 498151
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of cis-dichlorodiammine platinum (II) in patients undergoing hemodialysis].
Miyakawa M; Sugimoto K; Ohe Y; Masuoka H; Miyahara T
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2491-5. PubMed ID: 3619461
[TBL] [Abstract][Full Text] [Related]
7. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.
Bajorin DF; Bosl GJ; Alcock NW; Niedzwiecki D; Gallina E; Shurgot B
Cancer Res; 1986 Nov; 46(11):5969-72. PubMed ID: 3756934
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of cis-dichlorodiammineplatinum (II)].
Horiuchi M; Inuyama Y; Kohno N; Mashino S; Fujii M
Gan To Kagaku Ryoho; 1982 Apr; 9(4):632-7. PubMed ID: 6892197
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics of four platinum cytostatics in rats.
Láznícková A; Filipová M; Láznícek M; Drobník J; Svoboda D; Kvĕtina J
Neoplasma; 1987; 34(2):173-81. PubMed ID: 3600883
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum (II).
Vermorken JB; van der Vijgh WJ; Pinedo HM
Res Commun Chem Pathol Pharmacol; 1980 May; 28(2):319-28. PubMed ID: 7190316
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
Hohnloser JH; Schierl R; Hasford B; Emmerich B
Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
Ota K; Oguma T; Shimamura K
Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
